David Silverstein has over a dozen years of experience handling legal and regulatory matters relating to pharmaceutical and biotech products, having worked on the generic and the brand side.  He previously practiced in-house at Par Pharmaceutical and, prior to that, at major New York firms.  While in-house, David oversaw and managed all aspects of patent, antitrust, unfair competition and trade secret litigation.  He also served as Par’s in-house regulatory counsel, advising on regulatory strategies and frequently representing Par before FDA’s Office of Chief Counsel and other regulators.  

News

• Axinn Secures IPR Victory for Par in Challenge to Horizon’s Ravicti Patent
• Axinn Defeats TRO, Enabling Immediate Launch of Generic Versions of AstraZeneca’s Blockbuster Crestor
• Axinn Expands IP and Regulatory Practice with Partners David Silverstein and Aziz Burgy

Thought Leadership

• IPR Proceedings Survive Constitutional Challenge in 7-2 Supreme Court Ruling, BioWorld, April 24, 2018
• Scope of Patent Review, Deference At Issue, Westlaw Journal Intellectual Property, December 5, 2017

Events

Education

• JD – Duke University (2003)
• MS, Chemistry – Cornell University (1999)
• BS, Chemistry, magna cum laude – University of Georgia (1997)

Admissions

• New York
• US District Court Northern District of New York
• US District Court Southern District of New York
• US District Court Western District of New York
• US Patent and Trademark Office